Treatment of Patients With Acute Sinusitis

Completed

Brief Summary: For each patient, an initial visit and at least one follow-up visit at the end of treatment should be documented by the treating physician in the case report form.

Recruitment & Eligibility

Inclusion Criteria

Any patient with a diagnosis of acute bacterial sinusitis treated with Avelox® - in accordance with the local production information.

Exclusion Criteria

Those specified in the local product information - contraindications and precautions must be considered.

Arm && Interventions

Group	Intervention	Description
Group 1	Avelox (Moxifloxacin, BAY12-8039)	-

Primary Outcome Measures

Name	Time	Method
Evaluation of potential benefits of an antibacterial therapy with Avelox® (moxifloxacin) in patients with acute bacterial sinusitis to whom this treatment was prescribed. Especially the time to improvement and resolution of clinical signs and symptoms of	Documentation at baseline and at at least one follow-up visit. Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days).

Secondary Outcome Measures

Name	Time	Method
Evaluation of tolerability and safety of Avalox® in daily practice were investigated.	Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days).
Patient characteristics in acute bacterial sinusitis	Documentation at baseline visit.
History and frequency of sinusitis episodes	Documentation at baseline visit.
Diagnostic procedures and therapeutic options chosen by physicians in daily practice	Documentation at baseline visit.

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial